Wire Stories

Category Added in a WPeMatico Campaign

news_6

Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech’s Proposed High-Concentration Biosimilar (AVT02) for Humira®

Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023 All ongoing...

news_6

Orum Therapeutics to Present Preclinical Data for ORM-5029, a Novel Antibody Neodegrader Conjugate, at the AACR Annual Meeting 2022

BOSTON & DAEJEON, South Korea--(BUSINESS WIRE)--#AACR22--Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders, today announced...